Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

133
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
133
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

220
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
220
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

211
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
211
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

305
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
305

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High efficacy of BPaL among patients infected with <i>Mycobacterium tuberculosis</i> lineage 1 in the Philippines.

IJTLD open·2026
Same author

The time is now: making the case for compassionate use/pre-approval access to new TB drugs.

IJTLD open·2025
Same author

Laboratory strengthening strategies to advance drug susceptibility testing for BPaL regimens in TB treatment.

Public health action·2025
Same author

Treatment success rate and time to culture conversion under a prospective BPaL cohort study.

IJTLD open·2025
Same author

Treatment outcomes of pulmonary TB in adults in Indonesia.

IJTLD open·2025
Same author

Experiences in the introduction of bedaquiline pretomanid linezolid for drug-resistant tuberculosis in Kyrgyzstan.

Journal of clinical tuberculosis and other mycobacterial diseases·2024
Same journal

Mental health of healthcare workers in England during the first three years of the COVID-19 pandemic: The NHS CHECK study cohort.

PloS one·2026
Same journal

Research on trajectory tracking control of tracked vehicles based on hydraulic motor system identification and Laguerre-MPC.

PloS one·2026
Same journal

A collaborative cervical precancer screening strategy with concurrent HPV genotyping and visual inspection using alumni of a training centre across Ghana: The Rotary 'Protect Your Pearl' initiative.

PloS one·2026
Same journal

Removal efficiency of pesticide residues on pesticide-spiked Perilla Leaf and Broccoli surfaces using microplasma-treated water.

PloS one·2026
Same journal

Cross-domain zero-shot semantic segmentation for unstructured environments via EVA-CLIP model, ensemble prompt engineering, and optimized text-image matching.

PloS one·2026
Same journal

Adaptive robust sparse representation for face recognition based on weighted and fusion dictionary.

PloS one·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2025

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA
10:41

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA

Published on: April 30, 2020

13.9K

Introducing BPaL: Experiences from countries supported under the LIFT-TB project.

D F Wares1, M Mbenga1, V Mirtskhulava1

  • 1KNCV Tuberculosis Foundation, The Hague, The Netherlands.

Plos One
|November 19, 2024
PubMed
Summary
This summary is machine-generated.

The new 6-month BPaL regimen for drug-resistant tuberculosis (DR-TB) shows high success rates and is feasible across countries. This all-oral treatment is safe and effective for DR-TB patients.

More Related Videos

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

11.8K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K

Related Experiment Videos

Last Updated: Jun 7, 2025

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA
10:41

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA

Published on: April 30, 2020

13.9K
An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

11.8K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K

Area of Science:

  • Global Health
  • Infectious Diseases
  • Pharmacology

Background:

  • Drug-resistant tuberculosis (DR-TB) treatment historically involved long, toxic, and less effective regimens.
  • Recent advancements include the World Health Organization's 2020 guidelines recommending a 6-month all-oral BPaL (bedaquiline, pretomanid, linezolid) regimen for selected DR-TB patients under operational research (OR).

Purpose of the Study:

  • To assess the feasibility, effectiveness, and safety of introducing the BPaL regimen for DR-TB patients under operational research (OR) conditions.
  • To evaluate the implementation processes and challenges in 7 countries through the LIFT-TB project.

Main Methods:

  • The LIFT-TB project enrolled 574 DR-TB patients between November 2020 and March 2023 across 7 countries.
  • Operational research objectives focused on exploring BPaL regimen introduction feasibility and estimating its effectiveness and safety.

Main Results:

  • Interim treatment success rate reached 90.9% (280/308) among enrolled patients.
  • Adverse events of special interest (AESI) were common but manageable, with only one patient discontinuing treatment.
  • No unexpected adverse events (AE) were observed during the study period.

Conclusions:

  • The BPaL OR regimen proved feasible across diverse country settings with strong advocacy and partner communication.
  • Interim results demonstrate excellent patient responses, comparable to clinical trial outcomes.
  • Manageable adverse events and the absence of unexpected AEs support the safety profile of the BPaL regimen in real-world settings.